Mindray(SZ:300760) Sou Hu Wang·2025-12-02 10:56Core Viewpoint - The recent share buyback announcement by Mindray Medical (300760.SZ) has garnered significant attention in the capital market, signaling confidence from the company's management and potentially stabilizing the stock price [1][10]. Group 1: Share Buyback Details - On November 27, Chairman Li Xiting initiated a share buyback, purchasing 152,340 shares at an average price of 196.862 CNY per share, totaling approximately 29.99 million CNY [5]. - Li Xiting plans to continue buying shares over the next six months, with a total investment of 200 million CNY, funded by personal resources, without a fixed price range [5][6]. - Following the buyback, Li Xiting's direct shareholding increased, and he, along with his concerted parties, now controls 51.48% of the company's shares [5][6]. Group 2: Management Confidence - The buyback was followed by additional purchases from senior executives, including Senior Vice President Li Zaiwen, who bought 14,700 shares at an average price of 203.52 CNY per share on November 28 [4][6]. - The concentrated buying activity among the management team reflects a strong belief in the company's intrinsic value and future growth prospects [4][6]. Group 3: Market Reaction - Following the announcement, Mindray Medical's stock price rose by 3.93% to close at 204.01 CNY per share, with a trading volume of 2.378 billion CNY [13]. - The market response indicates that investors view the management's buyback as a positive signal, reinforcing their confidence in the company's long-term value [10][13]. Group 4: Company Performance - Mindray Medical is recognized as a leading domestic medical device company, with a projected revenue of 36.7 billion CNY in 2024 and a compound annual growth rate (CAGR) of over 18% from 2017 to 2024 [13]. - The company has maintained a net profit margin and return on equity (ROE) above 20%, highlighting its strong financial performance [13].